Los Angeles Capital Management LLC Sells 1,920 Shares of Intersect ENT, Inc. (NASDAQ:XENT)

Los Angeles Capital Management LLC reduced its stake in shares of Intersect ENT, Inc. (NASDAQ:XENT) by 4.6% during the fourth quarter, Holdings Channel reports. The institutional investor owned 40,269 shares of the medical equipment provider’s stock after selling 1,920 shares during the quarter. Los Angeles Capital Management LLC’s holdings in Intersect ENT were worth $922,000 at the end of the most recent quarter.

Several other large investors also recently made changes to their positions in XENT. FMR LLC grew its stake in shares of Intersect ENT by 1,863.8% during the first quarter. FMR LLC now owns 632,451 shares of the medical equipment provider’s stock valued at $20,334,000 after buying an additional 600,246 shares during the last quarter. HighMark Wealth Management LLC grew its stake in shares of Intersect ENT by 206.0% in the third quarter. HighMark Wealth Management LLC now owns 6,413 shares of the medical equipment provider’s stock worth $105,000 after purchasing an additional 4,317 shares during the last quarter. BNP Paribas Arbitrage SA increased its holdings in Intersect ENT by 24.0% during the 3rd quarter. BNP Paribas Arbitrage SA now owns 32,444 shares of the medical equipment provider’s stock valued at $529,000 after purchasing an additional 6,269 shares during the period. Great Lakes Advisors LLC increased its holdings in Intersect ENT by 17.5% during the 3rd quarter. Great Lakes Advisors LLC now owns 258,842 shares of the medical equipment provider’s stock valued at $4,222,000 after purchasing an additional 38,566 shares during the period. Finally, Jennison Associates LLC increased its holdings in Intersect ENT by 58.4% during the 3rd quarter. Jennison Associates LLC now owns 1,007,769 shares of the medical equipment provider’s stock valued at $16,437,000 after purchasing an additional 371,624 shares during the period. 84.32% of the stock is currently owned by hedge funds and other institutional investors.

XENT stock opened at $24.19 on Tuesday. Intersect ENT, Inc. has a fifty-two week low of $5.97 and a fifty-two week high of $26.98. The business’s 50 day moving average price is $24.15 and its two-hundred day moving average price is $20.29. The company has a debt-to-equity ratio of 0.72, a quick ratio of 10.29 and a current ratio of 11.28. The company has a market capitalization of $791.47 million, a price-to-earnings ratio of -12.66 and a beta of 1.34.

A number of research analysts recently issued reports on the company. SVB Leerink boosted their price target on Intersect ENT from $18.00 to $22.00 and gave the company a “market perform” rating in a report on Thursday, December 3rd. Canaccord Genuity upgraded Intersect ENT from a “hold” rating to a “buy” rating and boosted their price target for the company from $18.00 to $25.00 in a report on Monday, January 11th. BTIG Research upgraded Intersect ENT from a “neutral” rating to a “buy” rating and set a $32.00 price target on the stock in a report on Thursday, November 19th. Finally, Piper Sandler boosted their price target on Intersect ENT from $17.00 to $23.00 and gave the company a “neutral” rating in a report on Friday, January 15th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and three have given a buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus target price of $23.00.

Intersect ENT Profile

Intersect ENT, Inc, a drug delivery company, researches and develops products for the treatment of patients with ear, nose, and throat conditions in the United States. The company offers PROPEL and PROPEL mini drug releasing implants for patients undergoing sinus surgery to treat chronic sinusitis; and PROPEL Contour, a steroid releasing implant to frontal and maxillary sinus ostia, or openings, of the dependent sinuses.

Featured Story: Are sell-side analysts objective?

Want to see what other hedge funds are holding XENT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Intersect ENT, Inc. (NASDAQ:XENT).

Institutional Ownership by Quarter for Intersect ENT (NASDAQ:XENT)

Receive News & Ratings for Intersect ENT Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intersect ENT and related companies with MarketBeat.com's FREE daily email newsletter.